New system adds treatment options for Charcot foot and broadens the Company’s Extremity Fixation portfolio of products
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005144/en/

G-Beam Fusion Beaming System by
Designed primarily for the treatment of Charcot foot, a debilitating condition where the bones in the foot weaken and collapse, the G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.
“In my practice I often see patients whose uncontrolled diabetes has led
to the development of Charcot foot, an extremely disabling condition
that if left untreated, can lead to amputation,” said Dr.
When the use of internal fixation is recommended, the G-Beam system is designed to fuse the medial and/or lateral columns, as well as bones in the hindfoot, in order to restore a stable foot that may ultimately reduce the probability of an amputation. The system comes with single-use, sterile-packed implants and an efficient, compact instrumentation tray.
“The G-Beam Fusion Beaming System is the next step in working towards
our objective of becoming a recognized premium solution provider in the
Charcot and Diabetic foot market segments,” said
About Charcot Foot
Charcot foot is a chronic and progressive joint disease causing
weakening of the bones in the foot. It is a serious condition that can
lead to deformity, disability and even amputation. Charcot foot can
occur in people who have severe neuropathy (the loss of protective
sensation in the limb) or nerve damage, a common diabetic foot
complication. The
The G-Beam Fusion Beaming System will be on display during the
About
Orthofix International N.V. is a global medical device company focused on musculoskeletal healing products and value-added services. The Company’s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units: BioStim, Extremity Fixation, Spine Fixation, and Biologics. Orthofix products are widely distributed via the Company's sales representatives and distributors. For more information, please visit www.orthofix.com.
Forward Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of
View source version on businesswire.com: https://www.businesswire.com/news/home/20180322005144/en/
Source:
Orthofix International N.V.
Investor Relations
Mark Quick,
214-937-2924
markquick@orthofix.com
or
Media
Relations
Denise Landry, 214-937-2529
deniselandry@orthofix.com